Tanoğlu, AlpaslanÇağıltay, EylemTanoğlu, Esra GüzelGökhan, AylinŞirin, CansınÇavusoğlu, TürkerYeşilbaş, Soner2023-03-222023-03-2220221300-01441303-6165https://doi.org/10.55730/1300-0144.5483https://search.trdizin.gov.tr/yayin/detay/1145063https://hdl.handle.net/20.500.14034/605Background/aim: Nonalcoholic fatty liver is one of the most common forms of liver disease and role of microRNAs (miRNAs) on this illness is currently unclear. It was aimed to evaluate the predictive role of circulating miR-33a and mir-200c on high fructose corn syrup (HFCS)-induced fatty liver and vitamin D-3 supplementation-related hepatic changes. Materials and methods: Twenty-four rats were randomized into three groups: sham (n = 8), experimental fatty liver group (n = 8), and fatty liver + vitamin D-3 supplementation group (n = 8). In the treatment group, 10 mu g/kg/week of vitamin D-3 was given by orogastric tube weekly for 4 weeks in addition to a high fructose diet. Serum AST, ALT, TNF-alpha, and MDA levels were tested. Liver tissue samples were examined using hematoxylin/eosin, periodic acid-Schif (PAS) and Masson's Trichrome staining. Circulating miR-33a and mir-200c were quantified by qRT-PCR method. Moreover, in silico analyses were accomplished. Results: In the vitamin D-3 group, results of biochemical parameters were significantly different than those of the fatty liver group (p < 0.001). Moreover, significant differences in serum levels of circulating miR-33a and mir-200c were identified among all groups (p < 0.05). Finally, more favorable histopathological changes were noticed in the vitamin D-3 supplementation group. The expressions of Ki-67 were also considerably reduced in the vitamin D-3 group. According to KEGG pathway analysis, mir-33a and mir-200c were found to play a common role in the Hippo signaling pathway, lysine degradation, and protein processing. Conclusion: Our current experimental fatty liver study showed that, in a specified dose, vitamin D-3 supplementation could alleviate adverse undesirable hepatic effects of HFCS via miR-33a and mir-200c.eninfo:eu-repo/semantics/openAccessFatty livervitamin D-3microRNAbiomarkerratInsulin-ResistanceExpressionCholesterolRatsInflammationContributesDeficiencyDiseaseAlphaRiskArticle10.55730/1300-0144.548352514481457Q3WOS:0008909072000032-s2.0-85140291179114506336422507Q3